Cocrystal Pharma Q2 net loss $4.2M; cash $32.4M; advances antiviral pipeline

Cocrystal Pharma, Inc.

2023-Q2 EPS reported -$1.03

Net loss $4.2M ($0.41/share) vs $24.4M ($3.00) in Q2 2022, which included $19.1M goodwill impairment and legal settlement.
Cash $32.4M at June 30, 2023 vs $37.1M at Dec 31, 2022; management expects sufficient for 12 months.
On track to initiate Phase 2a trial for CC-42344 (influenza A) in H2 2023 pending UK MHRA clearance.
Selected novel protease inhibitor CDI-988 as lead oral norovirus candidate; Phase 1 cleared by Australian regulator.
Completed $4.0M private placement of common stock with directors Fred Hassan and Phillip Frost.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cocrystal Pharma, Inc. reported financial results for the three and six months ended June 30, 2023.

Period: the three and six months ended June 30, 2023
Result: reported results

Exact text from the filing

Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the three and six months ended June 30, 2023

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Cocrystal Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-029156

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.